Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II BRB regimen in relapsed Waldenstrom macroglobulinemia
2013-005129-22Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, rituximab and bendamustine in Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Started Mar 2014; status: completed.
02
Drugs
bortezomibrituximabbendamustine
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on 2013-005129-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005129-22.